{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetComparison",
 "url": "https://clearank.com/compare/gild-vs-bmy/",
 "dataUrl": "https://clearank.com/compare/gild-vs-bmy/data.json",
 "title": "GILD vs BMY: Which Is the Better Buy? (2026)",
 "description": "GILD or BMY? Compare GILD vs BMY, daily AI-powered analysis with technical indicators, price targets, valuation, and a head-to-head verdict.",
 "headline": "Gilead Sciences vs Bristol-Myers Squibb Company",
 "published": "2026-06-17T09:18:57+00:00",
 "modified": "2026-09-26T18:45:52.406+00:00",
 "generated": "2026-09-27T13:24:04.286Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "assets": [
  {
   "ticker": "GILD",
   "dataUrl": "https://clearank.com/stock/gilead-sciences-gild/data.json"
  },
  {
   "ticker": "BMY",
   "dataUrl": "https://clearank.com/stock/bristol-myers-squibb-bmy/data.json"
  }
 ],
 "sections": [
  {
   "id": "verdict",
   "title": "Comparative Analysis",
   "text": [
    "Bristol Myers Squibb (BMY) emerges as the preferred investment over Gilead Sciences (GILD) due to its superior profitability and more attractive valuation, despite GILD's stronger recent revenue growth. BMY demonstrates significantly higher net profit margins and return on equity, indicating more efficient operations and better shareholder value creation. While GILD has shown stronger recent revenue expansion, BMY's current financial health and valuation metrics present a more compelling case for investors seeking stability and efficiency in the pharmaceutical sector. BMY's current price of $62.86 is trading below its 50-day ($64.35) and 200-day ($59.14) moving averages, suggesting some short-term weakness but also potential for mean reversion. GILD, trading at $150.93, is above its 50-day ($141.48) and 200-day ($135.99) averages, indicating a more established uptrend. However, BMY's recent earnings beats and higher analyst target median relative to its current price offer a more immediate upside potential. The dividend yield also favors BMY, providing a higher income stream for investors.",
    "The decisive factor favoring Bristol Myers Squibb (BMY) is its demonstrably superior profitability. BMY's net profit margin and return on equity are substantially higher than GILD's, indicating a more efficient and financially sound operation. This profitability advantage, coupled with a more attractive valuation, presents a stronger case for investment despite GILD's more positive technical trend.",
    "Bristol Myers Squibb (BMY) is expected to see potential upside driven by its oversold technicals and strong profitability, assuming it can maintain its earnings momentum and navigate upcoming patent cliffs. A successful pipeline execution could see BMY re-test its 50-day moving average around $64.35 and potentially move higher. Gilead Sciences (GILD) is in a more established uptrend, supported by positive revenue growth and analyst optimism. However, its negative profit margins and lower dividend yield present headwinds. If GILD can improve its profitability and continue to grow revenue, it could challenge its 52-week high of $157.29. The next 6-12 months will be critical for both companies to demonstrate sustained earnings power and pipeline success."
   ]
  },
  {
   "id": "price",
   "title": "Price Analysis Comparison"
  },
  {
   "id": "valuation",
   "title": "Valuation Metrics",
   "text": [
    "Bristol Myers Squibb (BMY) presents a more attractive valuation with a Price-to-Earnings ratio of 13.47 compared to Gilead Sciences (GILD) at 17.87. This suggests BMY is cheaper on an earnings basis, offering more value for the price paid. Also, BMY's current price of $62.86 is closer to its 52-week low of $42.52 than GILD's price of $150.93 is to its 52-week low of $108.46. This positioning indicates that BMY may have more room for appreciation and is trading at a more significant discount relative to its recent trading range. GILD, while in a more established uptrend, is trading closer to its 52-week high, suggesting less immediate upside potential from a valuation perspective."
   ],
   "tables": [
    {
     "caption": "Valuation Metrics: GILD vs BMY",
     "columns": [
      "Metric",
      "GILD",
      "BMY"
     ],
     "rows": [
      {
       "label": "P/E Ratio",
       "cells": [
        "17.87",
        "13.47"
       ]
      },
      {
       "label": "Market Cap",
       "cells": [
        "187.15B",
        "128.41B"
       ]
      },
      {
       "label": "Price/Sales",
       "cells": [
        "6.16",
        "2.54"
       ]
      },
      {
       "label": "Price/Book",
       "cells": [
        "15.88",
        "5.60"
       ]
      },
      {
       "label": "EV/EBITDA",
       "cells": [
        "14.31",
        "8.39"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.15%",
        "3.99%"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "profitability",
   "title": "Profitability & Efficiency",
   "text": [
    "Bristol Myers Squibb (BMY) significantly outperforms Gilead Sciences (GILD) in profitability metrics. BMY boasts a net profit margin of 18.87% and a return on equity of 46.6%, demonstrating superior operational efficiency and ability to generate profits from shareholder investments. In contrast, GILD exhibits a negative net profit margin of -10.64% and a negative return on equity of -20.68%. While GILD's return on assets is a positive 14.09%, BMY's return on assets at 10.72% is lower, but its overall profitability picture is far stronger due to its positive net margin and ROE. These figures highlight BMY's stronger financial health and effective management of its resources."
   ],
   "tables": [
    {
     "caption": "Profitability & Efficiency: GILD vs BMY",
     "columns": [
      "Metric",
      "GILD",
      "BMY"
     ],
     "rows": [
      {
       "label": "Rev. Growth (Qtly)",
       "cells": [
        "10.20%",
        "5.70%"
       ]
      },
      {
       "label": "Profit Margin",
       "cells": [
        "-10.64%",
        "18.87%"
       ]
      },
      {
       "label": "Return on Equity",
       "cells": [
        "-20.68%",
        "46.60%"
       ]
      },
      {
       "label": "Return on Assets",
       "cells": [
        "14.09%",
        "10.72%"
       ]
      },
      {
       "label": "Debt/Equity",
       "cells": [
        "223.47",
        "201.86"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "earnings",
   "title": "Earnings Reality Check",
   "text": [
    "Last 5 Qs: GILD beat estimates 5x out of 5. Fell 3x after beats. (Sell the news?)",
    "Last 4 Qs: BMY beat estimates 4x out of 4. Rose 3x after beats."
   ]
  },
  {
   "id": "technicals",
   "title": "Technical Indicators",
   "text": [
    "Bristol Myers Squibb (BMY) is currently showing signs of weakness, with its RSI at 27.35 and CCI at -65.19, indicating oversold conditions and potential for a bounce. The stock is trading below its 20-day EMA ($63.65), 50-day SMA ($64.35), and 200-day SMA ($59.14), suggesting a bearish short-to-medium term trend. Gilead Sciences (GILD) presents a more constructive technical picture, with an RSI of 49.84 and CCI of 46.70, indicating neutral momentum. GILD is trading above its 20-day EMA ($148.17), 50-day SMA ($141.48), and 200-day SMA ($135.99), confirming an uptrend. However, BMY's oversold technicals suggest a higher probability of short-term price recovery compared to GILD's more stable but less immediately opportunistic trend."
   ],
   "tables": [
    {
     "caption": "Technical indicators: GILD vs BMY",
     "columns": [
      "Indicator",
      "GILD",
      "BMY"
     ],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "49.84",
        "27.35"
       ]
      },
      {
       "label": "50-Day MA",
       "cells": [
        "$141.48",
        "$64.35"
       ]
      },
      {
       "label": "200-Day MA",
       "cells": [
        "$135.99",
        "$59.14"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "sentiment",
   "title": "AI Analyst Sentiment",
   "text": [
    "Gilead Sciences (GILD) garners a more bullish analyst sentiment, with a median target price of $162, representing a potential upside of approximately 7.3% from its current price of $150.93. The analyst ratings are predominantly 'Strong Buy' and 'Buy'. Bristol Myers Squibb (BMY) also receives favorable analyst ratings, with a median target price of $68, suggesting an upside of approximately 8.2% from its current price of $62.86. While BMY has a higher proportion of 'Hold' ratings compared to GILD, the overall analyst consensus leans positive for both, with BMY offering a slightly better implied upside based on its current price relative to its median target.Note: While GILD shows stronger short-term technical momentum (Buy 72/100), the AI comparative analysis favors BMY (Hold 59/100) based on its overall trend structure, fundamentals, and risk-adjusted outlook."
   ]
  },
  {
   "id": "risk",
   "title": "Risk Stratification",
   "text": [
    "Bristol Myers Squibb (BMY) faces risks related to patent expirations for key drugs and increasing competition within the pharmaceutical market. Its recent negative EPS in one quarter, though a beat, highlights potential earnings volatility and the need for successful pipeline development to sustain growth. Gilead Sciences (GILD) carries risks associated with its significant debt load and the ongoing challenges in its antiviral and oncology segments. While GILD has shown revenue growth, its negative profit margins and return on equity indicate underlying operational inefficiencies or high cost structures that could hinder long-term profitability. Both companies are subject to regulatory changes and clinical trial outcomes, which can significantly impact their future prospects."
   ],
   "tables": [
    {
     "caption": "Risk metrics: GILD vs BMY",
     "columns": [
      "Metric",
      "GILD",
      "BMY"
     ],
     "rows": [
      {
       "label": "Beta (Volatility) i",
       "cells": [
        "0.35",
        "0.23"
       ]
      },
      {
       "label": "Sharpe Ratio",
       "cells": [
        "1.20",
        "0.61"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "protips",
   "title": "Comparative ProTips",
   "lists": {
    "ProTips": [
     "Consider BMY for its current profitability advantage and attractive valuation, with potential for a technical rebound.",
     "GILD remains in a technical uptrend, but its negative profit margins present a significant risk factor.",
     "Investors prioritizing income should favor BMY due to its higher dividend yield."
    ]
   }
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)"
  },
  {
   "id": "trade-plans",
   "title": "Actionable Trade Plans",
   "text": [
    "Compare entry, exit, and risk management levels for both assets",
    "Volatility-Adjusted Stop Loss Calculated based on volatility and technical support levels."
   ],
   "facts": {
    "STOP LOSS": "$57.93"
   }
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "VUG vs VOOG VUG vs VOOG Comparison $90.94 +0.5417%",
     "url": "https://clearank.com/compare/vug-vs-voog/"
    },
    {
     "text": "COP vs OXY COP vs OXY Comparison $127.30 -1.58%",
     "url": "https://clearank.com/compare/cop-vs-oxy/"
    },
    {
     "text": "SNPS vs CDNS SNPS vs CDNS Comparison $425.76 +0.2000%",
     "url": "https://clearank.com/compare/snps-vs-cdns/"
    },
    {
     "text": "GLD vs IAU GLD vs IAU Comparison $393.41 +0.4391%",
     "url": "https://clearank.com/compare/gld-vs-iau/"
    }
   ]
  }
 ],
 "faq": [
  {
   "question": "Which is a better buy, GILD or BMY?+",
   "answer": "BMY is a better buy due to its superior profitability (18.87% net margin vs GILD's -10.64%) and more attractive valuation (P/E of 13.47 vs GILD's 17.87). BMY also offers a higher dividend yield of 3.99% compared to GILD's 2.15%."
  },
  {
   "question": "What are the key risks for GILD vs BMY?+",
   "answer": "GILD faces risks from patent expirations and challenges in its core segments, alongside negative profit margins. BMY's risks include patent cliffs and competitive pressures, with recent earnings volatility also a concern."
  },
  {
   "question": "How do GILD and BMY compare on valuation?+",
   "answer": "BMY is cheaper with a P/E of 13.47 versus GILD's 17.87. BMY also trades closer to its 52-week low, suggesting more potential upside compared to GILD."
  },
  {
   "question": "Which stock offers a better dividend yield?+",
   "answer": "BMY offers a higher dividend yield of approximately 3.99%, compared to GILD's yield of approximately 2.15%."
  },
  {
   "question": "How do their recent earnings compare?+",
   "answer": "BMY had a strong earnings beat in its latest quarter (+27.5%), while GILD also beat estimates (+6.9%) but reported negative EPS. BMY's earnings history shows more consistent positive surprises."
  },
  {
   "question": "What are the technical outlooks for GILD and BMY?+",
   "answer": "GILD is in a confirmed uptrend, trading above key moving averages. BMY is showing oversold technicals (RSI 27.35) and trading below its averages, suggesting potential for a short-term rebound."
  },
  {
   "question": "Which company has better profitability metrics?+",
   "answer": "BMY demonstrates significantly better profitability with a net profit margin of 18.87% and a return on equity of 46.6%, whereas GILD has negative margins and ROE."
  }
 ],
 "related": {
  "peopleAlsoWatch": [],
  "comparisons": [
   {
    "ticker": "VUG vs VOOG",
    "name": "VUG vs VOOG Comparison",
    "price": "$90.94",
    "change": "+0.5417%",
    "url": "https://clearank.com/compare/vug-vs-voog/"
   },
   {
    "ticker": "COP vs OXY",
    "name": "COP vs OXY Comparison",
    "price": "$127.30",
    "change": "-1.58%",
    "url": "https://clearank.com/compare/cop-vs-oxy/"
   },
   {
    "ticker": "SNPS vs CDNS",
    "name": "SNPS vs CDNS Comparison",
    "price": "$425.76",
    "change": "+0.2000%",
    "url": "https://clearank.com/compare/snps-vs-cdns/"
   },
   {
    "ticker": "GLD vs IAU",
    "name": "GLD vs IAU Comparison",
    "price": "$393.41",
    "change": "+0.4391%",
    "url": "https://clearank.com/compare/gld-vs-iau/"
   }
  ],
  "Newly Tracked": [
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   },
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   },
   {
    "ticker": "SEI/USD",
    "text": "↑ 19.29%",
    "url": "https://clearank.com/crypto/sei-sei/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/GILD-vs-BMY-comparison-2026-06.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/GILD-vs-BMY-comparison-2026-06.png",
     "width": "1280",
     "height": "720",
     "caption": "Gilead Sciences (GILD) vs Bristol-Myers Squibb (BMY) stock comparison for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/compare/gild-vs-bmy/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/compare/gild-vs-bmy/",
        "name": "GILD vs BMY Comparison"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/compare/gild-vs-bmy/#webpage",
     "url": "https://clearank.com/compare/gild-vs-bmy/",
     "name": "GILD vs BMY: Which Is the Better Buy? (2026)",
     "datePublished": "2026-06-17T09:18:57+00:00",
     "dateModified": "2026-09-26T18:45:52+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/GILD-vs-BMY-comparison-2026-06.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/compare/gild-vs-bmy/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/compare/gild-vs-bmy/#richSnippet",
     "headline": "GILD vs BMY: Which Is the Better Buy? (2026)",
     "name": "GILD vs BMY: Which Is the Better Buy? (2026)",
     "description": "GILD or BMY? Compare GILD vs BMY, daily AI-powered analysis with technical indicators, price targets, valuation, and a head-to-head verdict.",
     "datePublished": "2026-06-17T09:18:57+00:00",
     "dateModified": "2026-09-26T18:45:52+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "isPartOf": {
      "@id": "https://clearank.com/compare/gild-vs-bmy/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/GILD-vs-BMY-comparison-2026-06.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/compare/gild-vs-bmy/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "ItemList",
   "name": "GILD vs BMY Comparison",
   "url": "https://clearank.com/compare/gild-vs-bmy/",
   "numberOfItems": 2,
   "itemListElement": [
    {
     "@type": "ListItem",
     "position": 1,
     "item": {
      "@type": "FinancialProduct",
      "name": "Gilead Sciences, Inc. (GILD)",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "GILD"
       }
      ],
      "description": "AI-driven analysis of Gilead Sciences, Inc. (GILD) - price targets, valuation, technicals.",
      "url": "https://clearank.com/stock/gilead-sciences-gild/"
     }
    },
    {
     "@type": "ListItem",
     "position": 2,
     "item": {
      "@type": "FinancialProduct",
      "name": "Bristol-Myers Squibb Company (BMY)",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "BMY"
       }
      ],
      "description": "AI-driven analysis of Bristol-Myers Squibb Company (BMY) - price targets, valuation, technicals.",
      "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Which is a better buy, GILD or BMY?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BMY is a better buy due to its superior profitability (18.87% net margin vs GILD's -10.64%) and more attractive valuation (P/E of 13.47 vs GILD's 17.87). BMY also offers a higher dividend yield of 3.99% compared to GILD's 2.15%."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key risks for GILD vs BMY?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "GILD faces risks from patent expirations and challenges in its core segments, alongside negative profit margins. BMY's risks include patent cliffs and competitive pressures, with recent earnings volatility also a concern."
     }
    },
    {
     "@type": "Question",
     "name": "How do GILD and BMY compare on valuation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BMY is cheaper with a P/E of 13.47 versus GILD's 17.87. BMY also trades closer to its 52-week low, suggesting more potential upside compared to GILD."
     }
    },
    {
     "@type": "Question",
     "name": "Which stock offers a better dividend yield?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BMY offers a higher dividend yield of approximately 3.99%, compared to GILD's yield of approximately 2.15%."
     }
    },
    {
     "@type": "Question",
     "name": "How do their recent earnings compare?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BMY had a strong earnings beat in its latest quarter (+27.5%), while GILD also beat estimates (+6.9%) but reported negative EPS. BMY's earnings history shows more consistent positive surprises."
     }
    },
    {
     "@type": "Question",
     "name": "What are the technical outlooks for GILD and BMY?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "GILD is in a confirmed uptrend, trading above key moving averages. BMY is showing oversold technicals (RSI 27.35) and trading below its averages, suggesting potential for a short-term rebound."
     }
    },
    {
     "@type": "Question",
     "name": "Which company has better profitability metrics?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "BMY demonstrates significantly better profitability with a net profit margin of 18.87% and a return on equity of 46.6%, whereas GILD has negative margins and ROE."
     }
    }
   ]
  }
 ]
}